ArticleArchives of toxicology2026
THP-1-derived polarized macrophages differ by drug transporter transcriptomics, P-glycoprotein activity and rifampicin uptake kinetics.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Rifabutin boosts rifampicin accumulation in THP-1-derived M2 macrophages by inhibiting P-glycoprotein efflux activity.Archives of toxicology · 2026Article
- Impact of rifampicin on P-glycoprotein (ABCB1) expression in M1 and M2 macrophages derived from the THP-1 monocytic cell line or peripheral blood mononuclear cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The striking divergence of ABCB1 mRNA expression and P-glycoprotein protein levels in M1 and M2 macrophages associates with the microRNA miR-21-3p, a regulator of "RNA binding protein, mRNA processing factor".Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inferior efficacy of antibiotics (e.g. rifampicin) in M2 macrophage-dominant tuberculosis granuloma might be related to poor drug uptake into these cells, potentially mediated by altered expression and activity of drug transporters such as P-glycoprotein (P-gp, encoded by ABCB1). Consequently, THP-1 cells were differentiated (200 nM phorbol 12-myristate 13-acetate; 72 h) and polarized to M1 (50 ng/mL lipopolysaccharide, 20 ng/mL interferon-gamma; 48 h) or M2 (20 ng/mL interleukin-4, interleukin-13; 48 h) macrophages. Then, quantitative polymerase-chain reaction array-based transcriptional analysis, flow cytometry, and ultra-performance liquid chromatography coupled to tandem mass spectrometry were used to evaluate the impact of differentiation and polarization on the expression levels of 84 drug transporter genes, the efflux activity of P-gp, and the cellular rifampicin uptake kinetics. ABCB1 was enhanced 166-fold during M1 polarization and 55-fold during M2 polarization. P-gp efflux activity in M2 cells was 1.55-fold higher than in M1 cells (P < 0.05). Rifampicin uptake into M2 cells was lower than into M1 cells after 2 h (P < 0.01) or 4 h exposure (P = 0.06) to 0.05 µM rifampicin. Together, when compared to M1 macrophages, M2 cells exhibit a considerably altered fingerprint of drug transporter expression levels, including an enhanced expression and activity of P-gp, being accompanied by lowered rifampicin uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.